Literature DB >> 18618224

Plasma Epstein-Barr viral load predicting response after chemotherapy for post-transplant lymphoproliferative disease.

Alex Sandro C Machado1, Alexandre Gustavo Apa, Lidia Maria Magalhães de Rezende, Nívea Dias Amoêdo, Franklin David Rumjanek, Carlos E Bacchi, Claudete Esteves Klumb.   

Abstract

Transplant patients are particularly at risk of developing B post-transplant lymphoproliferative disease (PTLD) related to intensive immunosuppressive treatment to prevent graft rejection. In EBV-positive PTLDs, EBV-DNA can be found in the patients' peripheral blood. Several methods have been described to assess peripheral blood EBV viral load. We report a case of a 13-year-old child who developed EBV-positive PTLD after renal transplantation. We assessed EBV plasma viral load by quantitative PCR and we found that the clearance of EBV-DNA correlated well with response to treatment.

Entities:  

Mesh:

Substances:

Year:  2008        PMID: 18618224     DOI: 10.1007/s10238-008-0168-9

Source DB:  PubMed          Journal:  Clin Exp Med        ISSN: 1591-8890            Impact factor:   3.984


  23 in total

1.  Mycophenolate mofetil increases cytomegalovirus invasive organ disease in renal transplant patients.

Authors:  J M Sarmiento; D H Dockrell; T R Schwab; S R Munn; C V Paya
Journal:  Clin Transplant       Date:  2000-04       Impact factor: 2.863

2.  Non-Hodgkin's lymphomas of childhood: an analysis of the histology, staging, and response to treatment of 338 cases at a single institution.

Authors:  S B Murphy; D L Fairclough; R E Hutchison; C W Berard
Journal:  J Clin Oncol       Date:  1989-02       Impact factor: 44.544

Review 3.  Epstein-Barr virus-induced posttransplant lymphoproliferative disorders. ASTS/ASTP EBV-PTLD Task Force and The Mayo Clinic Organized International Consensus Development Meeting.

Authors:  C V Paya; J J Fung; M A Nalesnik; E Kieff; M Green; G Gores; T M Habermann; P H Wiesner; J L Swinnen; E S Woodle; J S Bromberg
Journal:  Transplantation       Date:  1999-11-27       Impact factor: 4.939

4.  Characterization of Epstein-Barr virus-infected B cells in patients with posttransplantation lymphoproliferative disease: disappearance after rituximab therapy does not predict clinical response.

Authors:  J Yang; Q Tao; I W Flinn; P G Murray; L E Post; H Ma; S Piantadosi; M A Caligiuri; R F Ambinder
Journal:  Blood       Date:  2000-12-15       Impact factor: 22.113

Review 5.  Epstein-Barr virus and post-transplant lymphoproliferative disease.

Authors:  R D Holmes; R J Sokol
Journal:  Pediatr Transplant       Date:  2002-12

6.  Monitoring and modulation of Epstein-Barr virus loads in pediatric transplant patients.

Authors:  Rimas J Orentas; Dennis W Schauer; Frederick W Ellis; Joanna Walczak; James T Casper; David A Margolis
Journal:  Pediatr Transplant       Date:  2003-08

Review 7.  Herpesvirus infections in transplant recipients: current challenges in the clinical management of cytomegalovirus and Epstein-Barr virus infections.

Authors:  Raymund R Razonable; Carlos V Paya
Journal:  Herpes       Date:  2003-12

8.  Mycophenolate, tacrolimus and post-transplant lymphoproliferative disorder: a report of the North American Pediatric Renal Transplant Cooperative Study.

Authors:  Vikas R Dharnidharka; Ping-Leung Ho; Donald M Stablein; William E Harmon; Amir H Tejani
Journal:  Pediatr Transplant       Date:  2002-10

9.  Rituximab in the management of post-transplantation lymphoproliferative disorder after solid organ transplantation: proceed with caution.

Authors:  Sylvain Choquet; Stephan Oertel; Veronique LeBlond; Hanno Riess; Nathalie Varoqueaux; Bernd Dörken; Ralf Trappe
Journal:  Ann Hematol       Date:  2007-05-24       Impact factor: 3.673

10.  Geographic variation in Epstein-Barr virus-associated Burkitt's lymphoma in children from Brazil.

Authors:  Claudete Esteves Klumb; Rocio Hassan; Deilson Elgui De Oliveira; Lídia Maria Magalhães De Resende; Maria Kadma Carriço; Jane De Almeida Dobbin; Maria S Pombo-De-Oliveira; Carlos E Bacchi; Raquel Ciuvalschi Maia
Journal:  Int J Cancer       Date:  2004-01-01       Impact factor: 7.396

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.